首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >METRICS FOR LEVERAGING MORE IN CLINICAL DATA MANAGEMENT: PROOF OF CONCEPT IN THE CONTEXT OF VACCINE TRIALS IN AN INDIAN PHARMACEUTICAL COMPANY
【24h】

METRICS FOR LEVERAGING MORE IN CLINICAL DATA MANAGEMENT: PROOF OF CONCEPT IN THE CONTEXT OF VACCINE TRIALS IN AN INDIAN PHARMACEUTICAL COMPANY

机译:在临床数据管理中发挥更多作用的指标:印度药品公司疫苗试验背景下的概念证明

获取原文
       

摘要

The clinical trials data is of critical importance in providing evidence to support a drug or biologic product efficacy and safety. Quality data, productivityand lower product costs are key considerations in drug development process and to maintain competitive edge. Clinical Data Management(CDM) is a multistage process where various activities must be considered and decision taken in synergy and not sequentially; planned and executed according to the GCP (Good Clinical Practices) guidelines with highest standards. During the course of development, implementation and standardization of CDM procedures in the context of vaccine trialsin an Indian pharmaceutical company, it emerged that multi-factormetrics based performancemonitoring of critical procedural stepshave synergistic impact in boosting overall in-time progression of the projectand meeting desired data quality.It is important to acknowledge domain knowledge in developing performance metrics by involvingmembers of cross-functional teams. This report summarizes possible methodologies which if adopted are likely to keep the team members updated with the project advancement. The proof of concept,?createdin the form of metrics designed to drive performance improvement through appropriate levels of internal controls and characterizing progress made under each criteria, is expected to improve overall productivity by accomplishing the aim with desired quality and within stipulated time-frameby mitigating the errors. Key-words: Clinical Data Management (CDM), Indian Good Clinical Practices(GCP), CDM Metrics
机译:临床试验数据对于提供证据支持药物或生物制品的功效和安全性至关重要。质量数据,生产率和较低的产品成本是药物开发过程中保持竞争优势的关键考虑因素。临床数据管理(CDM)是一个多阶段过程,其中必须考虑各种活动,并协同而不是顺序地做出决定;根据具有最高标准的GCP(良好临床实践)指南进行计划和执行。在一家印度制药公司的疫苗试验中,在CDM程序的开发,实施和标准化过程中,发现基于多因素的关键程序步骤的性能监控在促进项目的整体及时进展和达到所需数据方面具有协同作用。质量。让跨职能团队的成员参与进来,在制定绩效指标时要承认领域知识很重要。本报告总结了可能采用的方法,这些方法如果采用,可能会使团队成员随时了解项目进展情况。可以通过适当的内部控制水平来表征绩效证明,并通过在每个标准下描述在每个标准下取得的进展来制定绩效指标,这种概念证明有望通过以所需的质量并在规定的时限内实现缓解目标的目标来提高总体生产率错误。关键字:临床数据管理(CDM),印度良好临床实践(GCP),CDM指标

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号